Assenagon Asset Management S.A. Trims Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. decreased its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 41.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,672 shares of the biotechnology company's stock after selling 80,184 shares during the quarter. Assenagon Asset Management S.A. owned about 0.53% of Enanta Pharmaceuticals worth $622,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares during the last quarter. GAMMA Investing LLC acquired a new position in shares of Enanta Pharmaceuticals during the first quarter valued at about $40,000. Intech Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at approximately $58,000. Squarepoint Ops LLC purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at approximately $66,000. Finally, Velan Capital Investment Management LP acquired a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $75,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENTA has been the topic of a number of recent analyst reports. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Enanta Pharmaceuticals Price Performance

ENTA traded down $0.05 during trading on Friday, reaching $7.18. 183,679 shares of the company's stock were exchanged, compared to its average volume of 285,759. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.09 and a 1 year high of $17.24. The company's fifty day simple moving average is $6.07 and its 200-day simple moving average is $6.08. The stock has a market capitalization of $153.49 million, a P/E ratio of -1.58 and a beta of 0.76.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 79.83% and a negative net margin of 149.57%. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.